Erasca Inc
Open
14.75 -3.97
Overzicht
Wijziging aandelenprijs
24u
Min
14.5
Max
15.66
Inkomsten | 139M -44M |
|---|---|
EPS | -0.14 |
Werknemers | 103 |
EBITDA | 139M -43M |
Aanbevelingen | Strong Buy |
|---|---|
12 Maanden Prognose | +57.27% upside |
Volgende Winsten | 10 nov 2026 |
|---|
Marktkapitalisatie | -638M 5.7B |
|---|---|
Vorige openingsprijs | 18.72 |
Vorige sluitingsprijs | 14.75 |
Erasca Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Erasca Inc Prognose
Koersdoel
By TipRanks
57.27% opwaarts potentieel
12 Maanden Prognose
Gemiddelde 24.125 USD 57.27%
Hoogste 33 USD
Laagste 20 USD
Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Erasca Inc - Dist. in de afgelopen 3 maanden.
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.